

Last Menstrual Period:


Ordering Physician:
Mary Cetan L.Ac.

DOB: 1945-10-05
Age: 74
Gender: Female




Collection Times:
2020-03-20 07:00AM
2020-03-20 08:30AM
2020-03-19 06:00PM
2020-03-21 11:00PM

Hormone Testing Summary

Key (how to read the results):




Sex Hormones See Pages 2 and 3 for a thorough breakdown of sex hormone metabolites



Progesterone Serum Equivalent is a calculated value based on urine pregnanediol.



Adrenal Hormones See pages 4 and 5 for a more complete breakdown of adrenal hormones




Free cortisol best reflects tissue levels. Metabolized cortisol best reflects total cortisol production.

Total DHEA Production

| Age | Range |
|-------|-----------|
| 20-39 | 1300-3000 |
| 40-60 | 750-2000 |
| >60 | 500-1200 |



cortisol
metabolism



The following videos (which can also be found on the website under the listed names along with others) may aid your understanding:

[DUTCH Complete Overview](#) [Estrogen Tutorial](#) [Female Androgen Tutorial](#) [Cortisol Tutorial](#)

PLEASE BE SURE TO READ BELOW FOR ANY SPECIFIC LAB COMMENTS. More detailed comments can be found on page 8.

- The patient shows significantly higher free cortisol compared to metabolized cortisol. It may be advisable to check thyroid hormones if you have not. See comments in the notes for more details.

**Accession # 00424271**

Jacquie Engle

**Sex Hormones and Metabolites****Last Menstrual Period:****Ordering Physician:**

Mary Cetan L.Ac.

DOB: 1945-10-05**Age:** 74**Gender:** Female**Collection Times:**

2020-03-20 07:00AM

2020-03-20 08:30AM

2020-03-19 06:00PM


2020-03-21 11:00PM

| Test | | Result | Units | Luteal* Range | Postmenopausal Range |
|--|-------------------------|--------|-------|------------------|-------------------------|
| Progesterone Metabolites (Urine) | | | | | |
| b-Pregnanediol | Below luteal range | 78.0 | ng/mg | 600 - 2000 | 60-200 |
| a-Pregnanediol | Below luteal range | 10.0 | ng/mg | 200 - 740 | 15-50 |
| Estrogens and Metabolites (Urine) | | | | | |
| Estrone(E1) | Below luteal range | 1.6 | ng/mg | 12 - 26 | 3.0-7.0 |
| Estradiol(E2) | Below luteal range | 0.15 | ng/mg | 1.8 - 4.5 | 0.2-0.7 |
| Estriol(E3) | Below luteal range | 0.7 | ng/mg | 5 - 18 | 0.6-4.0 |
| 2-OH-E1 | Below luteal range | 0.46 | ng/mg | 5.1 - 13.1 | 0.3-2.0 |
| 4-OH-E1 | Within luteal range | 0.19 | ng/mg | 0 - 1.8 | 0-0.3 |
| 16-OH-E1 | Below luteal range | 0.06 | ng/mg | 0.7 - 2.6 | 0.2-0.6 |
| 2-Methoxy-E1 | Below luteal range | 0.55 | ng/mg | 2.5 - 6.5 | 0.3-1.4 |
| 2-OH-E2 | Low end of luteal range | 0.06 | ng/mg | 0 - 1.2 | 0-0.3 |
| 4-OH-E2 | Within luteal range | 0.1 | ng/mg | 0 - 0.5 | 0-0.1 |
| 2-Methoxy-E2 | Within luteal range | 0.3 | ng/mg | 0 - 0.7 | 0-0.4 |
| Total Estrogen | Below range | 4.2 | ng/mg | 35 - 70 | 4.0-15 |
| Androgens and Metabolites (Urine) | | | | | |
| DHEA-S | Low end of range | 39.0 | ng/mg | 20 - 750 | |
| Androsterone | Low end of range | 219.0 | ng/mg | 200 - 1650 | |
| Etiocholanolone | Within range | 498.0 | ng/mg | 200 - 1000 | |
| Testosterone | Within range | 10.0 | ng/mg | 2.3 - 14 | |
| 5a-DHT | Low end of range | 1.3 | ng/mg | 0 - 6.6 | |
| 5a-Androstanediol | Below range | 9.2 | ng/mg | 12 - 30 | |
| 5b-Androstanediol | Within range | 48.3 | ng/mg | 20 - 75 | |
| Epi-Testosterone | Below range | 1.3 | ng/mg | 2.3 - 14 | |

*the Luteal Range is the premenopausal range. When patients are taking oral progesterone this range for progesterone metabolites is not luteal and reflects the higher levels expected when patients take oral progesterone. This test is intended to be taken in the luteal phase of the menstrual cycle (days 19-22 of a 28 day cycle) for premenopausal women. The ranges in the table below may be used when samples are taken during the first few days (follicular) of the cycle, during ovulation (days 11-14) or when patients are on oral progesterone. See the following pages for age-dependent ranges for androgen metabolites.

| Additional Normal Ranges | Follicular | Ovulatory | Oral Pg (100mg) |
|--------------------------|------------|-----------|-----------------|
| b-Pregnanediol | 100-300 | 100-300 | 2000-9000 |
| a-Pregnanediol | 25-100 | 25-100 | 580-3000 |
| Estrone (E1) | 4.0-12.0 | 22-68 | N/A |
| Estradiol (E2) | 1.0-2.0 | 4.0-12.0 | N/A |

Hormone metabolite results from the previous page are presented here as they are found in the steroid cascade. See the Provider Comments for more information on how to read the results.





Accession # 00424271
Jacquie Engle



Adrenal



Ordering Physician:
Mary Cetan L.Ac.

DOB: 1945-10-05
Age: 74
Gender: Female


Last Menstrual Period:

Collection Times:
2020-03-20 07:00AM
2020-03-20 08:30AM
2020-03-19 06:00PM
2020-03-21 11:00PM

| Category | Test | Result | Units | Normal Range |
|--|--------------------------------|-------------------|--------|-------------------|
| Creatinine (Urine) | | | | |
| | Creatinine A (Waking) | Below range | 0.18 | mg/ml 0.2 - 2 |
| | Creatinine B (Morning) | Below range | 0.14 | mg/ml 0.2 - 2 |
| | Creatinine C (Afternoon) | Below range | 0.1 | mg/ml 0.2 - 2 |
| | Creatinine D (Night) | Below range | 0.1 | mg/ml 0.2 - 2 |
| Daily Free Cortisol and Cortisone (Urine) | | | | |
| | Cortisol A (Waking) | High end of range | 43.4 | ng/mg 10 - 50 |
| | Cortisol B (Morning) | Within range | 87.2 | ng/mg 30 - 130 |
| | Cortisol C (Afternoon) | Within range | 13.8 | ng/mg 7 - 30 |
| | Cortisol D (Night) | High end of range | 13.7 | ng/mg 0 - 14 |
| | Cortisone A (Waking) | Within range | 99.3 | ng/mg 40 - 120 |
| | Cortisone B (Morning) | Within range | 163.9 | ng/mg 90 - 230 |
| | Cortisone C (Afternoon) | Low end of range | 43.7 | ng/mg 32 - 110 |
| | Cortisone D (Night) | High end of range | 47.8 | ng/mg 0 - 55 |
| | 24hr Free Cortisol | Within range | 158.0 | ng/mg 65 - 200 |
| | 24hr Free Cortisone | Within range | 354.7 | ng/mg 220 - 450 |
| Cortisol Metabolites and DHEA-S (Urine) | | | | |
| | a-Tetrahydrocortisol (a-THF) | Below range | 44.0 | ng/mg 75 - 370 |
| | b-Tetrahydrocortisol (b-THF) | Within range | 1407.0 | ng/mg 1050 - 2500 |
| | b-Tetrahydrocortisone (b-THE) | Below range | 1116.0 | ng/mg 1550 - 3800 |
| | Metabolized Cortisol (THF+THE) | Below range | 2567.0 | ng/mg 2750 - 6500 |
| | DHEA-S | Low end of range | 39.0 | ng/mg 20 - 750 |



At least one sample has a very low creatinine (female <0.15; male <0.2, see page 4), and for these individual samples cortisol & cortisone values may be somewhat less reliable.



The first value reported (Waking "A") for cortisol is intended to represent the "overnight" period. When patients sleep through the night, they collect just one sample. In this case, the patient did not report waking up during the night to collect a sample, so the "Waking (A)" cortisol and cortisone values should accurately represent the entirety of the overnight period.



Accession # 00424271

Jacque Engle



Organic Acid Tests (OATs)

Last Menstrual Period:

Ordering Physician:

Mary Cetan L.Ac.

DOB: 1945-10-05

Age: 74

Gender: Female

Collection Times:

2020-03-20 07:00AM

2020-03-20 08:30AM

2020-03-19 06:00PM

2020-03-21 11:00PM

| Category | Test | Result | Units | Normal Range |
|--|----------------------|------------------|-------|-----------------|
| Nutritional Organic Acids | | | | |
| Vitamin B12 Marker (may be deficient if high) - (Urine) | | | | |
| | Methylmalonate (MMA) | Within range | 1.2 | ug/mg 0 - 2.2 |
| Vitamin B6 Markers (may be deficient if high) - (Urine) | | | | |
| | Xanthurenate | Within range | 0.5 | ug/mg 0 - 1.4 |
| | Kynurenate | Within range | 2.7 | ug/mg 0 - 7.3 |
| Glutathione Marker (may be deficient if low or high) - (Urine) | | | | |
| | Pyroglutamate | Within range | 53.6 | ug/mg 32 - 60 |
| Neurotransmitter Metabolites | | | | |
| Dopamine Metabolite - (Urine) | | | | |
| | Homovanillate (HVA) | Above range | 19.5 | ug/mg 4 - 13 |
| Norepinephrine/Epinephrine Metabolite - (Urine) | | | | |
| | Vanilmandelate (VMA) | Above range | 9.4 | ug/mg 2.4 - 6.4 |
| Melatonin (*measured as 6-OH-Melatonin-Sulfate) - (Urine) | | | | |
| | Melatonin* (Waking) | Low end of range | 17.0 | ng/mg 10 - 85 |
| Oxidative Stress / DNA Damage, measured as 8-Hydroxy-2-deoxyguanosine (8-OHdG) - (Urine) | | | | |
| | 8-OHdG (Waking) | Within range | 3.1 | ng/mg 0 - 5.2 |

 **Steroid Pathways**
Find these **Hormones** on the DUTCH Report






1. Harnden, K. et al. Potential protective effect on key steroidogenesis and metabolic enzymes and sperm abnormalities by fenugreek extracts in tests and epididymis of surviving diabetic rats. *Arch Physiol Biochem*, 2010, **116**(3), p. 146-53.
2. Simonian, M.H. ACTH and thyroid hormone regulation of 3 beta-hydroxycholesterol dehydrogenase activity in human fetal adrenocortical cells. *J Steroid Biochem*, 1986, **25**(6), p. 1001-6.
3. Kaulaj, E.M. et al. Distribution of steroidogenic enzymes involved in androgen synthesis in polycystic ovaries: an immunohistochemical study. *Mol Hum Reprod*, 2000, **6**(5), p. 343-7.
4. Deluca, D., et al. Inhibition of 17beta-hydroxysteroid dehydrogenase by phytoestrogens: comparison with other steroid metabolizing enzymes. *J Steroid Biochem Mol Biol*, 2005, **93**(2-3), p. 285-92.
5. Zhang, S. et al. Fjordone disrupts of inhibiting testicular 3beta-hydroxysteroid dehydrogenase. *Chem Biol Interact*, 2019, **303**, p. 30-37.
6. Tomlinson, J.W. et al. Impaired glucose tolerance and insulin resistance are associated with increased adipose 17beta-hydroxysteroid dehydrogenase type 1 expression and elevated hepatic Sirtuin-6 dehydrogenase activity. *Diabetes*, 2008, **57**(10), p. 2652-60.
7. Stornati, M. et al. Six-month oral desmopressin and testosterone supplementation in early and late postmenopausal. *Gynecol Endocrinol*, 2000, **14**(5), p. 342-43.
8. Tsigos, C., J.W. Honour, and G.S. Conway. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. *J Clin Endocrinol Metab*, 2003, **88**(12), p. 5907-13.
9. Prager, N. et al. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of bioactive inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia. *J Altern Complement Med*, 2007, **8**(2), p. 143-52.
10. Fujita, R. et al. Androgenic activities of Genodermis (Ludum). *J Ethnopharmacol*, 2005, **102**(1-2), p. 107-12.
11. Morad, H.H. et al. The histological and histochemical effects of Urtica dioica extract on rat's prostate hyperplasia. *Vel Res Forum*, 2015, **6**(1), p. 23-9.
12. Witt, T. et al. Pregnenolone for benign prostatic hyperplasia. *Cochrane Database Syst Rev*, 2002(1), p. CD001044.
13. Azouzi, F. et al. The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. *Adv Urol*, 2012, **2012**, p. 530321.
14. Westphal, J. et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5alpha-reductase and lower cortisol conversion metabolite ratios in men with 'at risk' liver. *J Clin Endocrinol Metab*, 2003, **88**(10), p. 4924-31.
15. Garbinetti, A. et al. Increased clearance of cortisol by 5alpha-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. *J Endocrinol Invest*, 2003, **26**(2), p. 210-8.
16. Ogata, M. et al. The inhibitory effects of glycyrrhizin and glycyrrhetic acid on the metabolism of cortisol and prednisolone in vivo and in vitro studies. *Nihon Nishinpo Gakkaï Zasshi*, 1990, **66**(5), p. 584-96.
17. Dube, S. et al. 11beta-hydroxysteroid dehydrogenase types 1 and 2 activity in subcutaneous adipose tissue in humans: implications in obesity and diabetes. *J Clin Endocrinol Metab*, 2015, **100**(1), p. E70-6.
18. Stevens, C.L. et al. Proinflammatory cytokine induction of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in human adipocytes is mediated by NF-kappaB, CREB, and NF-ATc1. *J Clin Endocrinol Metab*, 2014, **99**(1), p. E16-8.
19. Chapman, K., W. Holmes, and J. Seckl. 11beta-hydroxysteroid dehydrogenase: intracellular glucose-keepers of tissue glucocorticoid action. *Physiol Rev*, 2013, **93**(3), p. 1339-206.
20. Hinzpeter, J. et al. Green tea and one of its constituents, Epigallocatechin-3-gallate, are potent inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. *Proc Soc Exp Biol Med*, 2014, **255**(1), p. 84-88.
21. Hu, G.X. et al. Curcumin as a potent and selective inhibitor of 11beta-hydroxysteroid dehydrogenase 1: improving lipid profiles in high-fat-diet-treated rats. *PLoS One*, 2013, **8**(3), p. e69076.
22. Adamovics, A.G. et al. Coffee inhibits the reactivation of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: a glucocorticoid connection in the anti-diabetic action of coffee? *FEBS Lett*, 2006, **580**(17), p. 4081-5.
23. Joffe Richard, E. et al. Anti-stress Activity of Ocimum sanctum: Possible Effects on Hypothalamic-Pituitary-Adrenal Axis. *Phytother Res*, 2016, **30**(5), p. 805-14.
24. Blum, A. et al. Monomelic charanville extract, a herbal remedy for type 2 diabetes, contains a specific 11beta-hydroxysteroid dehydrogenase type 1 inhibitor. *J Steroid Biochem Mol Biol*, 2012, **128**(1-2), p. 51-5.
25. Hosono, M. et al. Comprehensive study of urinary cortisol metabolites in hypertrophic and hypothyroid patients. *Clin Endocrinol (Oxf)*, 2006, **64**(1), p. 37-45.
26. Tanigawa, M., K. Hosono, and Y. Tanaka. Urinary cortisol metabolites in the assessment of peripheral thyroid hormone action: application for diagnosis of resistance to thyroid hormone. *Thyroid*, 1993, **3**(3), p. 229-33.
27. Uehara, H. et al. Decreased steroidogenic enzyme 17beta-HSD and increased 11beta-hydroxysteroid activities in type 2 diabetes mellitus. *Eur J Endocrinol*, 2002, **146**(3), p. 375-80.
28. Nestler, J.E. and D.J. Jankovic. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. *N Engl J Med*, 1996, **335**(9), p. 617-23.
29. Engelhardt, D. et al. The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. *Clin Endocrinol (Oxf)*, 1991, **35**(2), p. 163-8.
30. Kossor, D.C. and H.D. Goby. Dose-dependent actions of spironolactone on the inner and outer zones of the guinea pig adrenal cortex. *Pharmacology*, 1992, **45**(1), p. 27-35.
31. Hasegawa, E. et al. Effect of polyphenols on production of steroid hormones from human adrenocortical NCI-H295R cells. *Biol Pharm Bull*, 2013, **36**(2), p. 278-37.
32. Maru, N. et al. Bevacizumab inhibits androgen production of human adrenocortical H295R cells by lowering CYP17 and CYP21 expression and activities. *PLoS One*, 2017, **12**(3), p. e0174224.
33. Andric, S.A. et al. Acute effects of polyphenol-rich grapefruit-containing and free transformer fluids on rat testicular steroidogenesis. *Environ Health Perspect*, 2000, **108**(10), p. 955-9.
34. Kim, S.H. et al. Body fat mass is associated with Ratio of Steroid Metabolites reflecting 1720-ase Activity in Prepubertal Girls. *J Clin Endocrinol Metab*, 2016, **101**(12), p. 4653-60.
35. Arimura, D., G. Bornman, and M. Phermen. Reduction of serum testosterone in men by licorice. *J Biol Med*, 1995, **341**(5), p. 1158.
36. Arimura, D. et al. Licorice reduces serum testosterone in healthy women. *Steroids*, 2004, **69**(1-2), p. 73-6.
37. Scaramelli, P. and R.A. Lubo. The effects of spironolactone on adrenal steroidogenesis in hirsute women. *Fertil Steril*, 1985, **44**(5), p. 595-9.
38. Ayub, M. and M.J. Level. Inhibition of human adrenal steroidogenic enzymes in vitro by imidazole drugs including ketoconazole. *J Steroid Biochem*, 1983, **32**(4), p. 515-24.
39. Wang, X. et al. Suppression of rat and human androgen biosynthetic enzymes by adenosine: possible basis for the treatment of prostate cancer. *Endocrinology*, 2016, **111**(1), p. 66-72.
40. Hu, T. et al. Stromal adipose tissue activation by anti-androgens: polycystic ovary syndrome in rat. *Nat Rev Endocrinol*, 2017, **47**, p. 21-28.
41. Sertkaya, T. et al. Acute effect of adenosine on androgens in premenopausal women. *Alcohol Alcohol*, 2000, **35**(1), p. 64-90.
42. Cribaldi, A.M. et al. The effect of obesity on the ratio of type 3 17beta-hydroxysteroid dehydrogenase mRNA to cytochrome P450 aromatase mRNA in subcutaneous abdominal and intra-abdominal adipose tissue of women. *Int J Obes Relat Metab Disord*, 2002, **26**(2), p. 165-75.
43. Karszen, A. et al. Human 17beta-hydroxysteroid dehydrogenase type 3 is inhibited by dietary flavonoids. *Adv Exp Med Biol*, 2002, **505**, p. 151-61.
44. Le Bail, J.C. et al. Effects of phytoestrogens on aromatase, 3beta-hydroxysteroid dehydrogenase, and 17beta-hydroxysteroid dehydrogenase activities and human breast cancer cells. *J Steroid Biochem*, 2002, **66**(1), p. 1291-5.
45. Aghajani, S.O. and E.O. Faruqi. Quercetin ameliorates estradiol-induced changes in the testicular function of rats. *Toxicol Ind Health*, 2016, **32**(7), p. 1778-83.
46. Gerard, C. and K.A. Brown. Obesity and breast cancer: Role of estrogen and the molecular underpinnings of aromatase regulation in breast adipose tissue. *Mol Cell Endocrinol*, 2018, **466**, p. 15-30.
47. Rando, J.F. et al. The effect of insulin on aromatase activity in isolated human endometrial glands and stroma. *Am J Obstet Gynecol*, 1987, **157**(6), p. 1534-9.
48. Watanabe, M. and S. Nakajin. Forskolin up-regulates aromatase (CYP19) activity and gene transcripts in the human adrenocortical carcinoma cell line H295R. *J Endocrinol*, 2004, **180**(1), p. 125-33.
49. Sanderson, J.T. et al. Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. *Toxicol Sci*, 2004, **82**(1), p. 20-9.
50. Takeuchi, T. et al. Effect of paeoniflorin, glycyrrhizin and glycyrrhetic acid on ovarian androgen production. *Am J Chin Med*, 1991, **19**(1), p. 13-8.
51. Holbrook, A.C. et al. Arazene-induced changes in aromatase activity in estrogen sensitive target tissues. *J Appl Toxicol*, 2008, **28**(3), p. 260-70.
52. LePanth, E.D. Modulation of Aromatase by Phytoestrogens. *Enzyme Res*, 2015, **2015**, p. 592655.
53. Novales, M.H. et al. The effects of dietary supplementation with Arazene mushrooms and other medicinal fungi on breast cancer: evidence based medicine. *Clinics (Sao Paulo)*, 2011, **66**(12), p. 2133-9.
54. Sarah, K. et al. Inhibition of aromatase activity by green tea extract catechins and their endocrinological effects of oral administration in rats. *Food Chem Toxicol*, 2002, **40**(7), p. 925-33.
55. Eng, E.T. et al. Suppression of estrogen biosynthesis by procyanidin oligomers in red wine and grape seeds. *Cancer Res*, 2003, **63**(23), p. 8516-22.
56. Chen, J. et al. The correlation of aromatase activity and obesity in women with or without polycystic ovary syndrome. *J Ovarian Res*, 2015, **8**, p. 11.
57. Ayub, M. and M.J. Level. The inhibition of human prostatic aromatase activity by imidazole drugs including ketoconazole and 4-hydroxyandrostenedione. *Biochem Pharmacol*, 1990, **40**(7), p. 1569-75.
58. Rhee, S. et al. Dual effect of metformin on growth inhibition and oestrogen production in breast cancer cells. *Int J Med*, 2015, **35**(4), p. 1088-94.
59. Richard, S. et al. Differential effects of glypizate and orlistat on human placental cells and aromatase. *Environ Health Perspect*, 2005, **113**(6), p. 776-80.
60. Hodges, K.E. and D.M. Winick. Modulation of Metabolic Oxidation Pathways Using Food and Root-Derived Compounds: A Scientific Review with Clinical Application. *Nutr Metab*, 2015, **2015**, p. 760869.
61. Michonova, J.J. H. Adrecreutz, and H.L. Bradlow. Changes in levels of urinary estrogen metabolites after oral intake 3-carbonyl treatment in humans. *Nutr Cancer Res*, 1997, **8**(1), p. 718-23.
62. Somers, M.R. et al. Selected diet and lifestyle factors are associated with estrogen metabolites in a multicohort population of women. *J Nutr*, 2005, **136**(6), p. 1588-95.
63. Lu, L.J. et al. Increased urinary excretion of 2-hydroxyestrogen but not 16alpha-hydroxyestrogen in premenopausal women during a soy diet containing isoflavones. *Cancer Res*, 2000, **60**(5), p. 1299-305.
64. Chen, L.W. et al. The combined effects of garlic oil and fish oil on the hepatic antioxidant and drug-metabolizing enzymes of rats. *Br J Nutr*, 2003, **89**(2), p. 189-200.
65. Decker, P. et al. Induction of cytochrome P450 and/or detoxication enzymes by various extracts of rosemary: description of specific patterns. *Food Chem Toxicol*, 2001, **39**(9), p. 907-18.
66. Michonova, J.J. and S.A. Galbraith. Effects of exogenous phytoestrogens on C62 and C76 alpha hydroxylations of estradiol in humans. *Steroids*, 1990, **55**(1), p. 22-6.
67. Peters, L.P. and R.W. Teal. Effect of high sucrose diet on cytochrome P450 1A and heterocyclic amine mutagenesis. *Anticancer Res*, 2003, **23**(1A), p. 397-403.
68. Marabni, S. et al. Effects of low-to-moderate alcohol supplementation on urinary estrogen metabolites in postmenopausal women: a controlled feeding study. *Cancer Med*, 2017, **6**(10), p. 2419-2423.
69. Lictens, B. et al. Resveratrol and its methylated derivatives modulate the expression of estrogen metabolism enzymes in breast epithelial cells by Akt down-regulation. *Mol Cell Biochem*, 2017, **425**(1-2), p. 169-179.
70. Smidova, L. et al. Upregulation of CYP19B1 expression by inflammatory cytokines is mediated by the p38 MAP kinase signal transduction pathway. *Carcinogenesis*, 2014, **35**(11), p. 2534-43.
71. Li, M.Y. et al. Estrogen receptor alpha promotes smoking carcinogen-induced lung carcinogenesis via cytochrome P450 1B1. *Mol Med (Berl)*, 2015, **9**(91), p. 1221-33.
72. Jaramila, I.C. et al. Effects of Uterine components and combustion particle physicochemical properties on toxicological responses of lung cells. *Environ Sci Health A Toxic Hazard Subst Environ Res*, 2018, **53**(4), p. 295-309.
73. Doordyn, H., M.D. Burke, and R.T. Meyer. Biochemical selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. *Toxicology*, 2000, **144**(1-3), p. 31-8.
74. Whitten, D.L. et al. The effect of St. John's wort extracts on CYP3A4: a systematic review of prospective clinical trials. *Br J Clin Pharmacol*, 2006, **62**(3), p. 512-26.
75. Bradlow, H.L. et al. Effects of pesticides on the ratio of 16 alpha-bred 2-hydroxyestrogen to a biological marker of breast cancer risk. *Environ Health Perspect*, 1995, **103** Suppl 1, p. 147-50.
76. Luckert, C. et al. Polycyclic aromatic hydrocarbons stimulate human CYP3A4 promoter activity via PKR. *Toxicol Lett*, 2013, **222**(2), p. 180-8.
77. Wu, W.H. et al. Estrogenic effect of yam ingestion in healthy postmenopausal women. *Am J Clin Nutr*, 2005, **24**(4), p. 235-43.
78. Dresser, G.K. et al. Evaluation of propenyl ester oil and acetylglutamate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. *Clin Pharmacol Ther*, 2002, **72**(3), p. 247-55.
79. Nies, T., Y. Inagaki, and H. Yamazaki. Drug interactions between nine antifungal agents and drugs metabolized by human cytochrome P450. *Clin Drug Metab*, 2014, **15**(7), p. 63-79.
80. Jiang, H. et al. Human catechol-O-methyltransferase down-regulation by estradiol. *Neuropharmacology*, 2003, **45**(7), p. 1011-8.
81. Ho, P.W. et al. Effects of plasticizers and related compounds on the expression of the soluble form of catechol-O-methyltransferase in MCF-7 cells. *Curr Drug Metab*, 2008, **9**(4), p. 276-9.
82. Blum, K. et al. Manipulation of catechol-O-methyltransferase (COMT) activity to influence the attenuation of substance seeking behavior: a novel polyphenol: a hypothesis. *Mol Hypotheses*, 2007, **6**(95), p. 1054-60.
83. van Duren, M.B. et al. Phytochemicals inhibit catechol-O-methyltransferase activity in cytosolic fractions from healthy human mammary tissues: implications for catechol estrogen-induced DNA damage. *Toxicol Sci*, 2000, **81**(2), p. 16-24.
84. Sehlin, A.O. et al. St. John's wort may ameliorate 2,4,6-trinitrobenzenesulfonic acid colitis of rats through the induction of P-glycoprotein and P-glycoprotein. *Physiol Pharmacol*, 2015, **66**(2), p. 203-14.
85. Pascuzzi, J.M. et al. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. *Mol Pharmacol*, 2000, **58**(2), p. 361-72.
86. Zhou, H. and P.B. Hyslop. Bile acids are nutrient signaling hormones. *Steroids*, 2014, **86**, p. 62-8.
87. Ding, X. and J.L. Staudinger. Induction of drug metabolism by folic acid: the role of the pregnane X receptor and the protein kinase A signal transduction pathway. *J Pharmacol Exp Ther*, 2005, **312**(2), p. 869-85.
88. Mueller, J.W. et al. The Regulation of Steroid Action by Sulfation and Desulfation. *Endocr Rev*, 2015, **36**(3), p. 526-63.
89. Kim, M.S. et al. Suppression of CYP19A1 sulfotransferase (SULT2A1) during the acute phase response. *Am J Physiol Endocrinol Metab*, 2004, **287**(4), p. E731-8.
90. Al-Dhali, E.A. et al. Licorice and glycyrrhetic acid increase DHEA and dehydrocorticosterone levels in vivo and in vitro by inhibiting adrenal SULT2A1 activity. *Mol Cell Endocrinol*, 2011, **336**(1-2), p. 102-9.

ref 021720




Provider Notes

How to read the DUTCH report


This report is not intended to treat, cure or diagnose any specific diseases. The graphic dutch dials in this report are intended for quick and easy evaluation of which hormones are out of range. Results below the left star are shaded yellow and are below range (left). Results between the stars and shaded green are within the reference range (middle). Results beyond the second star and shaded red are above the reference range (right). Some of these hormones also change with age, and the age-dependent ranges provided should also be considered.



For female reproductive hormones, a purple band is present on the dutch dials. This band represents the expected levels (reference range) for postmenopausal (or non-cycling) women.



In a few places on the graphical pages, you will see fan-style gauges. For sex hormones, you will see one for the balance between 5a/5b metabolism as well as methylation. For adrenal hormones, you will see one to represent the balance between cortisol and cortisone metabolites. These indexes simply look at the ratio of hormones for a preference. An average or "normal" ratio between the two metabolites (or groups of metabolites) will give a result in the middle (as shown here). If the ratio between the metabolites measured is "low" the gauge will lean to the left and similarly to the right if the ratio is higher than normal.



Patient or Sample Comments

Throughout the provider comments you may find some comments specific to your situation or results. These comments will be found in this section or within another section as appropriate. Comments in other sections that are specific to your case will be in **bold**.

The patient reports no menstrual cycles.

Progesterone Metabolism

The primary role of progesterone is to balance the strong effects of estrogen. Progesterone metabolites are measured and reflect progesterone levels well because very little progesterone is found in urine, so b-Pregnanediol is typically used as a surrogate marker because it is the most abundant metabolite, but we also test the corresponding a-pregnanediol. The average of the two metabolites is reported for progesterone. If levels are in the lower part of the reference range compared to estrogen levels, symptoms of too much estrogen may occur.

When ordering the DUTCH Complete, you will see Progesterone Serum Equivalent on the summary page 1. The urine metabolites of progesterone have been proven to correlate strongly enough to serum progesterone to provide this value. The correlation is the strongest for values within the premenopausal luteal range. Urine metabolites can at times result in somewhat higher serum equivalent results in the postmenopausal range. For this reason the postmenopausal Serum Equivalent range is slightly higher than typical serum ranges. NOTE: If progesterone is taken orally (also with sublingual), these metabolites are elevated from gut metabolism and results do NOT accurately reflect serum levels.

The patient's progesterone metabolites show that she is in the menopausal range, as expected. Postmenopausal progesterone is produced by the adrenal glands (not the ovaries), so therapies that improve progesterone in cycling women may not help in menopause. Progesterone supplementation may be appropriate for improving energy, sleep and mood in post menopausal women, even when their levels are normal for a menopausal woman and may be appropriate if estrogen levels are higher than the postmenopausal levels.

Estrogen Metabolism

When evaluating estrogen levels, it is important to assess the following:

• The status (low, normal or high?) of estrogen production:

Levels of the primary ovarian product, estradiol (the strongest estrogen), as well as "total estrogens" may be considered. For women not on HRT, consider the appropriate range (premenopausal or postmenopausal).

• Phase I Metabolism:

Estrogen is metabolized (primarily by the liver) down three phase I pathways. The 2-OH pathway is considered the safest because of the anti-cancer properties of 2-OH metabolites. Conversely, the 4-OH pathway is considered the most genotoxic as its metabolites can create reactive products that damage DNA. The third pathway, 16-OH creates the most estrogenic of the metabolites (although still considerably less estrogenic than estradiol) - 16-OH-E1. If overall estrogen levels are high, production of 16-OH-E1 may exacerbate high estrogen symptoms. Similarly, a woman with very low levels of estrogens, may have less low estrogen symptoms if 16-OH metabolism is preferred. For example Armamento-Villareal showed that a higher 2-OH-E1/16-OH-E1 ratio correlated to bone loss (a low estrogen symptom). Estriol is thought of as a safer (weaker) estrogen metabolite, but it is important to remember that estriol is actually 16-OH-E2, so generally patients that make a lot of the potentially protective/weak estriol may also make a lot of the estrogenic 16-OH-E1.

When evaluating phase I metabolism, it may be important to look at the ratios of the three metabolites to see which pathways are preferred relative to one another. It may also be important to compare these metabolites to the levels of the parent hormones (E1, E2). If the ratios of the three metabolites are favorable but overall levels of metabolites are much lower than E1 and E2, this may imply sluggish phase I clearance of estrogens, which can contribute to high levels of E1 and E2. Similarly, patients with excessive phase I metabolism may have low E1 and E2 levels because of high rates of clearance (as opposed to simply not making a lot of estrogen).

The pie chart will assist you in comparing the three pathway options of phase I metabolism compared to what is "normal." 2-OH metabolism can be increased by using products containing D.I.M. or I-3-C. These compounds are found (or created from) in cruciferous vegetables and are known for promoting this pathway.

Phase I metabolism shows a preference for 2-OH metabolism, which is the protective pathway. The 4-OH and 16-OH pathways may be out of range despite this preference, so careful assessment is necessary. Products to increase 2-OH metabolism may be considered if E1 and E2 are elevated or if the 4-OH or 16-OH estrogens are high relative to 2-OH estrogens. Products that push the 2-OH pathway may also lower E1 and E2 levels, so keep this in mind when considering therapy.

• Methylation (part of phase II metabolism) of estrogens:

After phase I metabolism, both 4-OH and 2-OH (not 16-OH) estrogens can be deactivated and eliminated by methylation. The methylation-activity index shows the patient's ratio of 2-Methoxy-E1 / 2-OH-E1 compared to what is expected. Low methylation can be caused by low levels of nutrients needed for methylation and/or genetic abnormalities (COMT, MTHFR). The COMT enzyme responsible for methylation requires magnesium and methyl donors. Deficiencies in folate or vitamin B6 or B12 can cause low levels of methyl donors. MTHFR genetic defects can make it more difficult for patients to make sufficient methyl donors. Genetic defects in COMT can make methylation poor even in the presence of adequate methyl donors.

Androgen Metabolism

When evaluating androgen levels, it is important to assess the following:

• The status (low, normal or high?) of DHEA:

DHEA and androstenedione are made almost exclusively by the adrenal gland (although a smaller amount is made in the ovaries). These hormones appear in urine as DHEA-S (DHEA-Sulfate), androsterone and etiocholanolone. The best way to assess the total production of DHEA is to add up these three metabolites. This total can be seen on the first page of the DUTCH Complete (and DUTCH Plus). DHEA production decreases quite significantly with age. Age-dependent ranges can be seen on the graphical page of results.

The Total DHEA Production (page 1) was about 756ng/mg which is within the overall range and also within the age-dependent range for this patient. This implies that the adrenal glands are producing appropriate DHEA levels.

• The status (low, normal or high?) of testosterone:


Females make most of their DHEA in the adrenal gland and a fraction of that DHEA trickles down metabolically to testosterone. For premenopausal women, some testosterone is also made by the ovaries. Levels of testosterone do drop somewhat with age, but not to the degree that DHEA decreases.

Testosterone levels for this patient were approximately 10.0ng/mg, which is within range. If symptoms potentially related to high or low testosterone exist, you may also want to carefully evaluate 5a-metabolism (see below). You may also want to evaluate testosterone's downstream metabolites, 5a-androstanediol and 5b-androstanediol. These two metabolites generally parallel testosterone production, although they can also be generated from DHEA without going through testosterone.

• The metabolic preference for the 5a (5-alpha) or 5b (5-beta) pathway:

5a-reductase converts testosterone into 5a-DHT (DHT), which is even more potent (~3x) than testosterone. High levels of DHT can lead to symptoms associated with too much testosterone. Metabolites created down the 5b-pathway are significantly less androgenic than their 5a counterparts. In the examples below, the example on the left shows a patient with 5b-metabolism preference. A patient with a pattern like the example on the right may have high androgen symptoms even though the hormones are in the normal range because of the likely preference for turning a lot of her testosterone into DHT. The fan-style gauge below the hormones shows the 5a or 5b preference based on etiocholanolone (5b) and androsterone (5a) results. Progesterone metabolites are also metabolized by 5a and 5b enzymes and the balance between its two metabolites can be useful to confirm a 5a or 5b preference.

Example of how to read fan-style gauge for 5 α -reductase activity:



Neither testosterone or overall levels of DHEA are elevated, and 5 α -metabolism is not elevated. This is consistent with the patient's lack of reporting androgen excess symptoms.

It is important to consider DHEA and testosterone production, 5 α -metabolism patterns as well as the patient symptoms. For example, a woman with higher levels of DHEA and testosterone will often have high androgen symptoms (facial hair, thinning scalp hair, etc.) exacerbated by 5 α -metabolism. If, on the other hand, she prefers 5 β -metabolism she may not express high androgen symptoms in spite of higher levels of testosterone because 5 β is the less androgenic pathway. Testosterone levels may be better understood by also considering its downstream metabolites (5 α -androstanediol, 5 β -androstanediol). Technically, these metabolites can also be formed from DHEA metabolites without going through the testosterone pathway, but they generally tend to correlate with testosterone production. You will also see levels of epi-testosterone, which is not androgenic like testosterone. It happens to be produced in about the same concentrations as testosterone (this is an approximate relationship). This can be helpful to assess testosterone therapy and rare cases where testosterone may have other complexities.

DUTCH Adrenal

The HPA-Axis refers to the communication and interaction between the hypothalamus (H) and pituitary (P) in the brain down to the adrenal glands (A) that sit on top of your kidneys. When a physical or psychological stressor occurs, the hypothalamus tells the pituitary to make ACTH, a hormone. ACTH stimulates the adrenal glands to make the stress hormone, cortisol and to a lesser extent DHEA and DHEA-S. Normally, the HPA-axis production follows a daily pattern in which cortisol rises rather rapidly in the first 10-30 minutes after waking in order to help with energy, then gradually decreases throughout the day so that it is low at night for sleep. The cycle starts over the next morning. Abnormally high activity occurs in Cushing's Disease where the HPA-axis is hyper-stimulated causing cortisol to be elevated all day. The opposite is known as Addison's Disease, where cortisol is abnormally low because it is not made appropriately in response to ACTH's stimulation. These two conditions are somewhat rare. Examples of more common conditions related to less severely abnormal cortisol levels include fatigue, depression, insomnia, fibromyalgia, anxiety, inflammation and more.

Only a fraction of cortisol is "free" and bioactive. This fraction of cortisol is very important, but levels of metabolized cortisol best represent overall production of cortisol therefore both should be taken into account to correctly assess adrenal function.

When evaluating cortisol levels, it is important to assess the following:

- **The overall up-and-down pattern of free cortisol throughout the day, looking for low and high levels:**

Abnormal results should be considered along with related symptoms. Remember that with urine results, the "waking" sample reflects the night's total for free cortisol. The sample collected two hours after waking captures the cortisol awakening response, which is typically the time with the most cortisol secretion.

- **The sum of the free cortisol as an expression of the overall tissue cortisol exposure:**

This total of four free cortisol measurements is the best way to assess the total of free cortisol throughout the day, and this result correlates reasonably well to a true 24-hour urine free cortisol. Do be aware that this measurement does not take into account transitory shifts in cortisol in the late morning or early afternoon.

- **The total level of cortisol metabolites:**

We call this calculation "Metabolized Cortisol" which is the sum of a-THF, b-THF and b-THE (the most abundant cortisol metabolites). While free cortisol is the best assessment for tissue levels of cortisol, it only represents 1-3% of the total produced. The majority of cortisol results in a urine metabolite and the total of these metabolites best represents the total glandular output of cortisol for the day. When overall production is much higher than free cortisol levels, cortisol clearance may be increased (as seen in hyperthyroidism, obesity, etc.) The most common reason for sluggish cortisol clearance (assumed when free cortisol levels are much higher than metabolized cortisol) is low thyroid.

Overall free cortisol levels are within range, but metabolized cortisol (the best marker for overall cortisol production) is low. This implies that overall HPA-Axis A is low. Cortisol clearance may be a bit sluggish, which keeps free cortisol levels within range in spite of low overall production. Hypothyroidism and other conditions

may lead to slow cortisol metabolism. If treating the patient for potential thyroid issues be sure to take into account the interplay between the thyroid and adrenals.

• **A potential preference for cortisol or cortisone (the inactive form):**

Looking at the comparison between the total for free cortisol and free cortisone is NOT the best indication of a person's preference for cortisol or cortisone. The kidney converts cortisol to cortisone in the local tissue. This localized conversion can be seen by comparing cortisol (free) and cortisone levels. To see the patient's preference systemically, it is best to look at which *metabolite* predominates (THF or THE). This preference can be seen in the fan style gauge. This is known as the 11b-HSD index. The enzyme 11b-HSD II converts cortisol to cortisone in the kidneys, saliva gland and colon. 11b-HSD I is more active in the liver, fat cells and the periphery and is responsible for reactivating cortisone to cortisol. Both are then metabolized by 5a-reductase to become tetrahydrocortisol (THF) and tetrahydrocortisone (THE) respectively.

The OATs are tested from the morning "A" sample. These values are most reliable when the creatinine value for this sample is >0.2mg/mL for female and >0.3mg/mL for male patients. These values may be less reliable with a highly dilute sample with very low creatinine values.

Nutritional Organic Acids

The following four organic acids are functional markers for vitamin deficiency. These compounds essentially back up in human biochemistry when a key nutrient is missing. These three metabolites have fairly straightforward interpretations. When the markers are elevated, it is likely that the patient's cellular levels of the related nutrient may be insufficient.

Methylmalonate (MMA)

Methylmalonate (also known as methylmalonic acid or MMA) is a functional marker of vitamin B12 (also known as cobalamin) deficiency. When cellular levels of B12 are low either from deficiency or due to a B12 transporter gene mutation, levels of MMA increase. This marker is considered superior to measuring serum B12 levels directly. A 2012 publication by Miller showed that 20% of those tested had a genetic defect in the protein that transports B12 to cells. These patients may have a functional B12 deficiency even if serum levels of B12 are normal.

If levels of MMA are elevated, it may be advisable to increase B12 consumption. Common foods high in B12 include beef liver, sardines, lamb, wild caught salmon, grass-fed beef, nutritional yeast and eggs. Vitamin B12 levels can also be increased through supplementation of B12 (taken as cobalamin, methylcobalamin, hydroxycobalamin, or adenosylcobalamin). Symptoms of a vitamin B12 deficiency include: fatigue, brain fog, memory problems, muscle weakness, unsteady gait, numbness, tingling, depression, migraines/headaches and low blood pressure.

Xanthurenate

Xanthurenate (also known as xanthurenic acid) and Kynurenate (kynurenic acid) are functional markers of vitamin B6 (also known as pyridoxine) deficiency. Vitamin B6 is a critical co-factor to over 100 important reactions that occur in the human body and is stored in the highest concentrations in muscle tissue. Tryptophan is readily converted to NAD by the liver. One of the steps in this pathway requires B6. When there is insufficient B6, xanthurenate is made instead. Kynurenate may also become elevated when patients are B6 deficient because of a different, possibly less B6 dependent pathway. The pathways leading to these biomarkers have other influences, so they will not always agree. When Xanthurenate is elevated, Kynurenate is also elevated about 1/3 of the time. When both are elevated, a B6 deficiency is likely more certain and more severe. Not only is xanthurenate an indicator of a lack of B6, it is also harmful to the human body. It complexes with insulin and decreases insulin sensitivity. In fact, rats fed xanthurenate will actually develop diabetes because of the effects on insulin. If xanthurenate levels are elevated, B6 supplementation may be considered. Food high in B6 include turkey breast, grass-fed beef, pinto beans, avocado, pistachios, chicken, sesame and sunflower seeds.

While there is always some tryptophan going down the kynurenine pathway towards NAD (and possibly xanthurenate), this process is up-regulated by inflammation, estrogen and cortisol. If levels of estrogen or cortisol are high, it may exacerbate xanthurenate elevations and increase the need for B6.

Xanthurenate can also bind to iron and create a complex that increases DNA oxidative damage resulting in higher 8-OHdG levels. If both markers are elevated, there is likely an antioxidant insufficiency.

Pyroglutamate

Pyroglutamate (also known as pyroglutamic acid) is a functional marker of glutathione deficiency. Pyroglutamate is a step in the production/recycling of glutathione. If the body cannot convert pyroglutamate forward, it will show up elevated in the urine. High pyroglutamate is an established marker for glutathione deficiency. Pyroglutamate in the urine can also be elevated with cheese consumption.

Glutathione is one of the most potent anti-oxidants in the human body. It is especially important in getting rid of toxins, including the reactive quinone species formed by 4-OH-E1 and 4-OH-E2. This reactive species can damage DNA if not detoxified by either methylation or glutathione.

Some have reported that low pyroglutamate may also be indicative of a need for glutathione; however, this is not established in the scientific literature.

Neurotransmitter Metabolites

The neurotransmitters dopamine and norepinephrine are important for human health. Measuring neurotransmitters directly (direct testing of dopamine, for example) is difficult because of their instability and their urinary measurements are controversial with respect to how well they reflect the body's levels of these neuro-hormones. Each of these two neurotransmitters can be assessed indirectly by measuring their urine metabolites. While these metabolites are not a perfect reflection of what's going on in the brain, the scientific literature does affirm their use for a good representation of overall levels of these neurotransmitters.

Homovanillate (HVA)

Homovanillate (also known as HVA) is the primary metabolite of dopamine, a brain and adrenal neurotransmitter that comes from tyrosine (with BH4 and iron as co-factors) and goes on to create norepinephrine (noradrenaline) and epinephrine (adrenaline).

Low levels of HVA can be due to low levels of dopamine or poor conversion of dopamine to HVA. The latter may be due to insufficient levels of SAM, Magnesium, FAD and NAD which are needed to metabolize dopamine. Low circulating dopamine may be due to insufficient BH4, iron or tyrosine. It may also be seen when adrenal function is generally low. Low dopamine levels may be associated with addictions, cravings and pleasure seeking (to boost levels) in addition to sleepiness, impulsivity, tremors, less motivation, fatigue and low mood.

Elevated HVA may be caused by generally increased adrenal hormone output or because of a copper or vitamin C deficiency (which are needed for dopamine conversion to norepinephrine). Elevations may also be caused by a number of medications or supplements including: MAO inhibitors, quercetin, tyrosine, DL-phenylalanine (DLPA), L-dopa, macuna, dopamine medication (Levodopa, Sinemet, Methyl dopa), SNRI medication (Wellbutrin), tricyclic antidepressants, amphetamines, appetite suppressants, and caffeine. Bananas also contain dopamine. Elevated dopamine may be associated with loss of memory, insomnia, agitation, hyperactivity, mania, hyper-focus, high stress and anxiety as well as addictions, cravings and pleasure seeking (to maintain high levels).

When HVA is very high, consider if the previously discussed foods, supplements or medications may be the cause. Rarely, tumors associated with increased HVA may be present. In these cases, further testing is necessary for diagnosis. High HVA alone is not diagnostic of a tumor.

Vanilmandelate (VMA)

Vanilmandelate (also known as VMA) is the primary metabolite of norepinephrine and epinephrine (adrenaline). The adrenal gland makes cortisol and DHEA as well as norepinephrine and epinephrine. When adrenal hormone output is generally low, VMA levels may be low. If HVA levels are significantly higher than VMA, there may be a conversion problem from dopamine to norepinephrine. This case can be caused by a copper or vitamin C deficiency. The enzymes COMT (methylation) and MAO are needed to make VMA from norepinephrine. If these enzymes are not working properly, VMA may be low when circulating norepinephrine and/or epinephrine are not low. Low levels of norepinephrine and epinephrine may be associated with addictions, cravings, fatigue, low blood pressure, low muscle tone, intolerance to exercise, depression, loss of alertness. When the body is under physical or psychological stress, VMA levels may increase. Because dopamine gets converted to norepinephrine and ultimately to VMA, the list of medications and supplements that increase HVA may also increase VMA. Elevated levels may be associated with feeling stressed, aggression, violence, impatience, anxiety, panic, worry, insomnia, paranoia, increased tingling/burning, loss of memory, pain sensitivity, high blood pressure and heart palpitations. If VMA and HVA are both extremely high, it may be necessary to rule out a neuroblastic tumor.

Melatonin (measured as 6-OHMS)

Melatonin is not technically an adrenal or sex hormone however it is highly involved in the entire endocrine system. It is made in small amounts in the pineal gland in response to darkness and stimulated by Melanocyte Stimulating Hormone (MSH). A low MSH is associated with insomnia, an increased perception of pain, and mold exposure. Pineal melatonin (melatonin is also made in significant quantities in the gut) is associated with the circadian rhythm of all hormones (including female hormone release). It is also made in small amounts in the bone marrow, lymphocytes, epithelial cells and mast cells. Studies have shown that a urine sample collected upon waking has levels of 6-Hydroxymelatonin-sulfate (6-OHMS) that correlate well to the total levels of melatonin in blood samples taken continuously throughout the night. The DUTCH test uses the waking sample only to test levels of melatonin production.

Low melatonin levels may be associated with insomnia, poor immune response, constipation, weight gain or increased appetite. Elevated melatonin is usually caused by ingestion of melatonin through melatonin supplementation or eating melatonin-containing foods. Elevated melatonin production that is problematic is rare, but levels can be higher in patients with Chronic Fatigue Syndrome and may be phase shifted (peaking later) in some forms of depression.

8-OHdG (8-Hydroxy-2-deoxyguanosine)

8-OHdG (8-hydroxy-2-deoxyguanosine) results can be seen on page 6 of the DUTCH Complete (or DUTCH Plus) report. It is a marker for estimating DNA damage due to oxidative stress (ROS creation). 8-OHdG is considered pro-mutagenic as it is a biomarker for various cancer and degenerative disease initiation and promotion. It can be increased by chronic inflammation, increased cell turnover, chronic stress, hypertension, hyperglycemia/pre-diabetes/diabetes, kidney disease, IBD, chronic skin conditions (psoriasis/eczema), depression, atherosclerosis, chronic liver disease, Parkinson's (increasing levels with worsening stages), Diabetic neuropathy, COPD, bladder cancer, or insomnia. Studies have shown higher levels in patients with breast and prostate cancers. When levels are elevated it may be prudent to eliminate or reduce any causes and increase the consumption of antioxidant containing foods and/or supplements.

The reference range for 8-OHdG is a more aggressive range for Functional Medicine that puts the range limit at the 80th percentile for each gender. A classic range (average plus two standard deviations) would result in a range of 0-6ng/mg for women and 0-10ng/mg for men. Seeking out the cause of oxidative stress may be more crucial if results exceed these limits.

Urine Hormone Testing - General Information

What is actually measured in urine? In blood, most hormones are bound to binding proteins. A small fraction of the total hormone levels are "free" and unbound such that they are active hormones. These free hormones are not found readily in urine except for cortisol and cortisone (because they are much more water soluble than, for example, testosterone). As such, free cortisol and cortisone can be measured in urine and it is this measurement that nearly all urinary cortisol research is based upon. In the DUTCH Adrenal Profile the diurnal patterns of free cortisol and cortisone are measured by LC-MS/MS.

All other hormones measured (cortisol metabolites, DHEA, and all sex hormones) are excreted in urine predominately after the addition of a glucuronide or sulfate group (to increase water solubility for excretion). As an example, Tajic (Natural Sciences, 1968 publication) found that of the testosterone found in urine, 57-80% was testosterone-glucuronide, 14-42% was testosterone-sulfate, and negligible amounts (<1% for most) was free testosterone. The most likely source of free sex hormones in urine is from contamination from hormonal supplements. To eliminate this potential, we remove free hormones from conjugates (our testing can be used even if vaginal hormones have been given). The glucuronides and sulfates are then broken off of the parent hormones, and the measurement is made. These measurements reflect the bioavailable amount of hormone in most cases as it is only the free, nonprotein-bound fraction in blood/tissue that is available for phase II metabolism (glucuronidation and sulfation) and subsequent urine excretion.

Disclaimer: the filter paper used for sample collection is designed for blood collection, so it is technically considered "research only" for urine collection. Its proper use for urine collection has been thoroughly validated.

Reference Range Determination (last updated 12.20.2018)

We aim to make the reference ranges for our DUTCH tests as clinically appropriate and useful as possible. This includes the testing of thousands of healthy individuals and combing through the data to exclude those that are not considered "healthy" or "normal" with respect to a particular hormone. As an example, we only use a premenopausal woman's data for estrogen range determination if the associated progesterone result is within the luteal range (days 19-21 when progesterone should be at its peak). We exclude women on birth control or with any conditions that may be related to estrogen production. Over time the database of results for reference ranges has grown quite large. This has allowed us to refine some of the ranges to optimize for clinical utility. The manner in which a metabolite's range is determined can be different depending on the nature of the metabolite. For example, it would not make clinical sense to tell a patient they are deficient in the carcinogenic estrogen metabolite, 4-OH-E1 therefore the lower range limit for this metabolite is set to zero for both men and women. Modestly elevated testosterone is associated with unwanted symptoms in women more so than in men, so the high range limit is set at the 80th percentile in women and the 90th percentile for men. Note: the 90th percentile is defined as a result higher than 90% (9 out of 10) of a healthy population.

Classic reference ranges for disease determination are usually calculated by determining the average value and adding and subtracting two standard deviations from the average, which defines 95% of the population as being "normal." When testing cortisol, for example, these types of two standard deviation ranges are effective for determining if a patient might have Addison's (very low cortisol) or Cushing's (very high cortisol) Disease. Our ranges are set more tightly to be optimally used for Functional Medicine practices.

Below you will find a description of the range for each test:

| Female Reference Ranges (Updated 08.21.2019) | | | | | | | | | |
|--|------|-------|------|------|-----------------------|------|-------|------|------|
| | Low% | High% | Low | High | | Low% | High% | Low | High |
| b-Pregnanediol | 20% | 90% | 600 | 2000 | Cortisol A (waking) | 20% | 90% | 10 | 50 |
| a-Pregnanediol | 20% | 90% | 200 | 740 | Cortisol B (morning) | 20% | 90% | 30 | 130 |
| Estrone (E1) | 20% | 80% | 12 | 26 | Cortisol C (~5pm) | 20% | 90% | 7 | 30 |
| Estradiol (E2) | 20% | 80% | 1.8 | 4.5 | Cortisol D (bed) | 0 | 90% | 0 | 14 |
| Estriol (E3) | 20% | 80% | 5 | 18 | Cortisone A (waking) | 20% | 90% | 40 | 120 |
| 2-OH-E1 | 20% | 80% | 5.1 | 13.1 | Cortisone B (morning) | 20% | 90% | 90 | 230 |
| 4-OH-E1 | 0 | 80% | 0 | 1.8 | Cortisone C (~5pm) | 20% | 90% | 32 | 110 |
| 16-OH-E1 | 20% | 80% | 0.7 | 2.6 | Cortisone D (bed) | 0 | 90% | 0 | 55 |
| 2-Methoxy-E1 | 20% | 80% | 2.5 | 6.5 | Melatonin (6-OHMS) | 20% | 90% | 10 | 85 |
| 2-OH-E2 | 0 | 80% | 0 | 1.2 | 8-OHdG | 0 | 90% | 0 | 5.2 |
| 4-OH-E2 | 20% | 80% | 0 | 0.5 | Methylmalonate | 0 | 90% | 0 | 2.2 |
| 2-Methoxy-E2 | 20% | 80% | 0 | 0.7 | Xanthurenate | 0 | 90% | 0 | 1.4 |
| DHEA-S | 20% | 90% | 20 | 750 | Kynurenate | 0 | 90% | 0 | 7.3 |
| Androsterone | 20% | 80% | 200 | 1650 | Pyroglutamate | 10% | 90% | 32 | 60 |
| Etiocolanalone | 20% | 80% | 200 | 1000 | Homovanillate | 10% | 95% | 4 | 13 |
| Testosterone | 20% | 80% | 2.3 | 14 | Vanilmandelate | 10% | 95% | 2.4 | 6.4 |
| 5a-DHT | 20% | 80% | 0 | 6.6 | | | | | |
| 5a-Androstenediol | 20% | 80% | 12 | 30 | Calculated Values | | | | |
| 5b-Androstenediol | 20% | 80% | 20 | 75 | Total DHEA Production | 20% | 80% | 500 | 3000 |
| Epi-Testosterone | 20% | 80% | 2.3 | 14 | Total Estrogens | 20% | 80% | 35 | 70 |
| a-THF | 20% | 90% | 75 | 370 | Metabolized Cortisol | 20% | 90% | 2750 | 6500 |
| b-THF | 20% | 90% | 1050 | 2500 | 24hr Free Cortisol | 20% | 90% | 65 | 200 |
| b-THE | 20% | 90% | 1550 | 3800 | 24hr Free Cortisone | 20% | 90% | 220 | 450 |
| % = population percentile: Example - a high limit of 90% means results higher than 90% of the women tested for the reference range will be designated as "high." | | | | | | | | | |

Provider Notes:



424271

Requisition Accession

2020-03-31

Engle, Jacquie



FORM

tchtest

BY PRECISION ANALYTICAL INC.

Provider Section - Completion Required for Testing

ORDERING HEALTHCARE PROVIDER

Nature's Wisdom Healing Center
Mary Cetan, L.Ac.4920 Fruitville Rd
Sarasota, FL 34232
Kit Number : 1117369

Billing(BP)

☒ **Dutch Complete****Adrenal + Sex Hormone Metabolites + OATs**Cortisol (4), Cortisone (4), Cortisol Metabolites (3), Creatinine (4),
Progesterone (2), Androgen (8), Estrogen Metabolites (10), 8-OHdG,
Melatonin (6-OHMS), Organic Acid Tests (6)☐ **Dutch Adrenal**

Cortisol (4), Cortisone (4), Creatinine (4), Cortisol Metabolites (3), DHEA-S

☐ **Dutch Sex Hormone Metabolites**

Progesterone (2), Androgen (8), Estrogen Metabolites (10)

☐ **Dutch OATs**

Organic Acid Tests (6), 8-OHdG, Melatonin (6-OHMS)

ICD-10 Codes (USA Only) Write in one or more codes.

Codes pertaining to adrenal hormones (optional):

Codes pertaining to sex (reproductive) hormones (optional):

BOTH SIDES OF FORM MUST BE COMPLETED

Fill out with blue or black ink only

PATIENT INFORMATION

REQUIRED

Patient Name (last, first)

Engle, Jacquie

Date of Birth (MM/DD/YY)

10/15/1945

Height

5' 2"

Weight

118

☒ Female☐ Male

Email Address

Address

City

State

Zip

Country

Day Phone

Cell Phone

☐ Hispanic or Latino☐ Native Hawaiian or Pacific Islander☐ Asian☐ Black or African American☐ Native American or Alaska Native☐ White

WOMEN

Menstrual Cycles

☐ None ☐ Regular ☐ Irregular

Have you had any ovaries removed?

☐ Yes ☐ No

If Yes, how many?

☐ One ☐ TwoFirst Day of Last Menses
(MM/DD/YY)Pregnant: ☐ Yes ☐ NoBirth Control: ☐ Yes ☐ No

If Yes, please specify

SAMPLE COLLECTION DATE AND TIME

Sample 1 - DINNER TIME ~5pm

Date

3/19/2020

Time

6

☐ AM☒ PM

Sample 2 - BEDTIME ~10pm

Date

3/19/2020

Time

11pm

☐ AM☒ PM

Sample 3 - IMMEDIATELY AT WAKING/RISING

Date

3/20/2020

Time

7

☒ AM☐ PM

Sample 4 - 2-HR AFTER WAKING

Date

3/20/2020

Time

8:30

☒ AM☐ PM

Extra OVERNIGHT Sample - Optional

Date

3/21/2020

Time

11

☐ AM☒ PM

Did you urinate overnight without collecting a sample?

☐ Yes☒ No

HORMONE, SUPPLEMENT AND PRESCRIPTION INFORMATION

Please complete the following information for any **progesterone, estrogens, DHEA, testosterone, pregnenolone, melatonin** or **cortisol** (cortef, hydrocortisone, etc.) you are taking. "Date Last Used" should be the last time you took the hormone before finishing the test.

For Route of Administration (ROA) list one of the following: 1=oral, 2=sublingual (under the tongue, between cheek/gum), 3=transdermal (skin) cream, 4=transdermal (skin) gel, 5=vaginal/labial creams/inserts, 6=rectal mucosa, 7=patch, 8=pellet, 9=injection, 10=other

| Hormone | Brand | ROA (1-10) | Dose (mg) | Date Last Used | Times Per Day | Length of Use |
|---------|-------|------------|-----------|----------------|---------------|---------------|
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

☐ Not taking any listed hormones

PLEASE INDICATE IF YOU ARE TAKING ANY OF THE FOLLOWING PRESCRIPTIONS:

- ☐ DIM / I-3-C ☐ Thyroid (T3, T4) ☐ Hydrocortisone Cream ☐ Steroid Inhaler ☐ Steroid Nasal Spray
- ☐ Glucocorticoid (Prednisone, Dexamethasone, etc.) ☐ Creatine ☐ Diabetes Medications
- ☐ Opioid (Narcotic) Pain Medications (hydrocodone, fentanyl, codeine, oxycodone, etc.)
- ☐ Blood Pressure Medications ☐ 5-HTP ☐ Anti-Depressants/SSRIs _____ (type)

LAB USE ONLY

Per Oregon State Requirements, Test
Order Co-signed by Carrie Jones, ND

RESOLVED by

Date 03/31/2020

RECEIVED
MAR 27 2020

DISEASE STATES

| | I do not suspect I have this | I suspect I may have this | I have been diagnosed with this |
|------------------------------|------------------------------|-------------------------------------|-------------------------------------|
| Addison's Disease | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Adrenal Insufficiency | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Chronic Fatigue | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Cushing's Disease | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| High Blood Pressure | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Hyperthyroidism (Overactive) | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Hypothyroidism (Underactive) | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> |
| Kidney Disease | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Type 2 Diabetes | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Polycystic Ovary Syndrome | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

FATIGUE

Please Rate Your Fatigue Level During The Day

| | 0 | 1 | 2 | 3 |
|--------------------|-------------------------------------|-------------------------------------|--------------------------|--------------------------|
| 0 = Never/None | | | | |
| 1 = Sometimes/Mild | | | | |
| 2 = Often/Moderate | | | | |
| 3 = Always/Severe | | | | |
| Morning Fatigue | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Afternoon Fatigue | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Evening Fatigue | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

Please List any Current/Recent Medical Diagnosis Not Listed Elsewhere On This Form

PLEASE CIRCLE SYMPTOMS YOU ARE EXPERIENCING AND RATE THE OVERALL CATEGORY.

0 = Never/None 1 = Sometimes/Mild 2 = Often/Moderate 3 = Always/Severe

| Women | | 0 | 1 | 2 | 3 | Men | | 0 | 1 | 2 | 3 |
|---------------------|--|-------------------------------------|-------------------------------------|--------------------------|--------------------------|---------------------|--|--------------------------|--------------------------|--------------------------|--------------------------|
| Androgen Excess | Loss of Scalp Hair, Increased Body or Facial Hair, Acne | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Androgen Excess | Increased Sex Drive, Body, or Facial Hair, Aggressive Behavior, Acne | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Androgen Deficiency | Vaginal Dryness, Decreased Sex Drive, Libido | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Androgen Deficiency | Decreased Libido, Erections, or Muscle Size, Increased Belly Fat, Apathy | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Estrogen Excess | Tender or Fibrocystic Breasts, Mood Swings, Uterine Fibroids, Heavy Bleeding | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | Estrogen Excess | Weight Gain (Breast or Hips), Prostate Problems | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Estrogen Deficiency | Hot Flashes, Night Sweats, Vaginal Dryness | <input type="checkbox"/> | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | | | | | | |

ADDITIONAL SYMPTOMS

 0 = Never/None
 1 = Sometimes/Mild
 2 = Often/Moderate
 3 = Always/Severe

| | 0 | 1 | 2 | 3 |
|------------------------|-------------------------------------|--------------------------|--------------------------|--------------------------|
| Trouble Falling Asleep | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Trouble Staying Asleep | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Depression | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Anxiety | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |
| Migraines | <input checked="" type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> | <input type="checkbox"/> |

WHICH BEST DESCRIBES YOU?

- ☐ Underweight
☒ At ideal weight
☐ 5-20 lbs Overweight
☐ >20 lbs Overweight

 Are you struggling to lose weight? ☐ Yes ☐ No

WHAT ARE THE TOP ISSUES YOU HOPE THIS TEST WILL HELP YOU RESOLVE?

 Check thyroid.
 UTI - re-occurring repeatedly

PLEASE LIST ANY ADDITIONAL MEDICATION

Have been in freezer since testing collection of samples

Patient notes — please list anything about your sample collection or medical situation that you feel may be important for this lab test.

 Forgot and had some beer (light) after test 1 and before test 2.
 Repeated test 2 on extra (overnight) sample without alcohol before test #2

BOTH SIDES MUST BE COMPLETED



001117369